Pfizer has terminated a Phase II study of its CD47 immune checkpoint inhibitor, maplirpacept, due to low recruitment. In an ...

Pfizer insists that the discontinuation of the Phase II study was due to recruitment difficulties and was not linked to ...

A former Pfizer scientist was subpoenaed Monday by House Republicans over allegations that senior executives at the pharma ...

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

The FDA has updated its warnings about potential cardiac risks associated with Pfizer and Moderna COVID-19 vaccines, ...

The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

Pfizer has reported positive topline outcomes from the multicentre, open-label Phase III BASIS trial of Hympavzi.

Sigvotatug Vedotin is an ADC that targets integrin αvβ6-positive tumor cells. It has an engineered antibody that ensures high ...

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...

Pfizer has discontinued its Phase 1b/2 trial of maplirpacept (PF-07901801), a CD47-blocking agent, in combination with ...